Bio2business - BOS cmc - 17th June 2010, Sohuset Conference Center, Horsholm, Copenhagen, Denmark

Attending Biotech and Pharma

Bioregion and
conference Partners

Why attend BOS cmc ?
• Network with your peers from international biotech & pharma early scale-up and development.
• Exchange ideas and transfer knowledge with regards to successful outsourcing.
• Hear from leading authorities in key areas of cmc outsourcing
• Organise 1:1 meetings with leading development vendors and industry consultants.

Welcome to the Biotech Outsourcing Strategies (BOS) series of forums devised and managed by Bio2Business Ltd (www.bio2business.com). BOS is the evolution of an ongoing 5 year project by Bio2Business Ltd to facilitate R&D outsourcing and partnering for international biotech and pharmaceutical companies.

A Day of Partnering & Networking

BOS cmc is primarily a partnering event; a forum to connect international biotech & pharma outsourcing executives with a network of specialist CROs. As a delegate attending BOS cmc in Copenhagen you can expect to meet with a significant number of top quality niche global CROs at the development interface who offer high quality, reliable services. You will be able to organise 1 to 1 meetings with CROs, consultants and fellow development executives as you wish throughout the day using Bio2Business partnering software. Informal networking over coffee, lunch and closing drinks receptions will give you an ideal opportunity to make links with fellow development executives and exchange ideas and approaches to outsourcing.

The partnering software is due to go live from Monday, 17th May.

Speaker Programme

In addition to providing a partnering forum for attendees, BOS cmc also strives to deliver an outstanding programme of speakers to deliver perspective and approaches in the field of scale-up from Early Development to Phase II-III. This year we are pleased to announce two lecture streams, running concurrently featuring a small molecule and a new biologics focused stream.

The first class programme of speakers for our small molecule stream includes:

Dr Christoph Rosenbohm,Director Chemistry & CMC, Santaris Pharma A/S; Prof Per-Goran Gillberg, VP Development, Albireo Pharma AB; Dr Signe Maria Christensen, CMC Co-ordinator, NeuroSearch A/S; Prof Graham Buckton, CEO, Pharmaterials Ltd; Dr Paul Brian Little, Director of Chemistry, Manufacturing & Controls, 7TM Pharma A/S; Dr Hans Lindner, Head of Pharmaceutical Development, Bayer Schering Pharma AG.

The esteemed programme of speakers for our biologics stream includes:

Dr Soren Bregenholt, COO, Symphogen A/S; Dr Andreas Castan, Director Upstream Development, Biovitrum AB; Dr Christian G Houghton, Senior Director, Global Product Development,ALK; Dr Jesper Valbjoern, Director CMC Operations, Genmab A/S; Dr Grethe Rasmussen, VP Product Development, Ascendis Pharma; Dr Jesper Sonne Johansen, Senior CMC Project Manager, Novo Nordisk A/S.

Our speakers are international experts in their fields of specialization including, preclinical programme management, building CMC work packages managing outsourcing partnerships, etc. We believe such a blend of speakers talking about critical areas of cmc scale up and development from Big Pharma and Biotech will provide a unique perspective on current approaches in cmc outsourcing.